-

Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity

original (Photo: Business Wire)

(Photo: Business Wire)

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette has already commenced commercial shipments, triggering the 180 days exclusivity.

Apurva Saraf, President and CEO of Cosette Pharma, stated, "This approval and immediate launch represents an important milestone in the evolution of Cosette, and reaffirms our commitment to world class R&D and operational excellence. Since we reset and refocused our R&D efforts in mid-2020, we now have several niche ANDAs pending with the FDA and look forward to the future approvals and launches."

This launch will enable Cosette to continue to build upon its unparalleled quality track record and leverage its United States based manufacturing site in Lincolnton, NC.

About Cosette Pharmaceuticals, Inc.:

Cosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids/solutions, suppositories, and injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (New Jersey and North Carolina) supported by more than 350+ dedicated employees across all functional areas. Cosette has a fast-growing portfolio of branded pharmaceuticals, consisting of products in cardiology, women’s health and pediatrics. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. www.cosettepharma.com

Follow us on LinkedIn.

TAZORAC® is registered trademark of Almirall

Contacts

Serge Ilin-Schneider: bd@cosettepharma.com
Kian Kazemi: sales@cosettepharma.com

Industry:

Cosette Pharmaceuticals, Inc.

Details
Headquarters: Bridgewater, New Jersey, USA
CEO: Apurva Saraf
Employees: 350
Organization: PRI
Release Summary
Cosette Pharmaceuticals Announces Launch of First Generic Versions of TAZORAC® (tazarotene) gel with 180 days Competitive Generic Therapy exclusivity
Release Versions
English
Hashtags
#abreva
#alembic
#cosettepharma
#growth
#health
#healthcare
#pharmaceuticalindustry
#pharmaceuticalmanufacturing
#pharmaceuticals
#privateequity

Contacts

Serge Ilin-Schneider: bd@cosettepharma.com
Kian Kazemi: sales@cosettepharma.com

Social Media Profiles
Cosette Pharmaceuticals, Inc.
More News From Cosette Pharmaceuticals, Inc.

Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. In this critical role, Jeff will lead Cosette’s best-in-class quality and regulatory affairs organizations, maintaining the company’s rigorous quality standards and further establishing Cosette’s strong position as a respected and reliable supplier of high-quality medicines....

Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total consideration of approximately USD $430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma’s Board of Directors has unanimously recomm...

Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations....
Back to Newsroom